The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | MDS: what’s the impact of early diagnosis?
David Steensma
• 5 Mar 2020
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses myelodysplastic syndromes (MDS) diagnostic patterns, early versus later diagnosis and the impact on patient outcomes. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
